Purple Biotech Ltd ADR Dossier - Source-backed chat

Purple Biotech Ltd ADR

PPBTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.02

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.52Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.5M

Enterprise Value −$6.2M

Shares Outstanding 1.6M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Purple Biotech Ltd. is a clinical-stage oncology company that has strategically pivoted to focus on its next-generation tri-specific antibody platform, CAPTN-3, led by the candidate IM1240. While the company recorded a significant non-cash impairment on its clinical-stage assets (CM24 and NT219) in late 2025 due to partnering dependencies, the CAPTN-3 platform represents a highly innovative approach to immuno-oncology. Preclinical data presented at EACR 2026 validated the platform's conditional activation masking design, showing an improved safety and pharmacokinetic profile in non-human primates. With a cash runway extending into 2027, the company is well-positioned to advance IM1240 toward first-in-human trials in 2027, offering high-upside optionality for risk-tolerant biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$30.00

Mean target$30.00

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company faces delays in IND-enabling toxicology or manufacturing scale-up for IM1240, pushing the first-in-human trial timeline beyond 2027. Additionally, the search for a new CEO is prolonged, creating governance uncertainty. With no strategic partner secured for CM24 or NT219, the company is forced to execute highly dilutive equity raises to fund operations as its cash runway nears its end in early 2027.

Base CaseCentral scenario

The company successfully advances its lead tri-specific antibody candidate, IM1240, through IND-enabling studies, keeping it on track for a first-in-human clinical trial in 2027. Gil Efron's transition from CEO to leading corporate development in August 2026 proceeds smoothly, and a qualified successor is appointed. The cash runway of $6.4 million (as of March 31, 2026) sustains operations into 2027, allowing the company to secure a strategic partnership or non-dilutive funding to support clinical entry.

Bull CaseUpside scenario

Successful clinical entry of IM1240 in 2027 and validation of the CAPTN-3 platform, combined with securing a strategic partner for CM24/NT219, unlocking significant valuation upside toward the analyst consensus target of $30.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated CAPTN-3 tri-specific antibody platform designed to engage both T cells and NK cells while conditionally activating only in the tumor microenvironment, minimizing systemic toxicity.
Strong preclinical validation for lead candidate IM1240, including favorable pharmacokinetic and cytokine-release safety profiles demonstrated in non-human primates (presented at EACR 2026).
Strategic pivot to preclinical assets preserves cash, extending the operational runway into 2027 with $6.4 million in cash as of Q1 2026.
Gil Efron will continue to lead corporate development post-CEO transition, ensuring continuity in strategic partnership and financing discussions.

Key Investment Risks

High binary clinical and regulatory risk typical of early-stage biotechnology companies.
Sidelined clinical-stage assets (CM24 and NT219) require external partnerships or additional financing to resume development, following a $20.5 million impairment charge in 2025.
Potential shareholder dilution if strategic partnerships or non-dilutive funding are not secured before the cash runway expires in 2027.
Upcoming leadership transition in August 2026 introduces execution and governance risks.

Thesis Invalidation Triggers

Failure to appoint a qualified successor CEO by August 2026 or disruption during the leadership transition.
Unfavorable toxicology or manufacturing issues that delay the planned 2027 first-in-human clinical trial for IM1240.
Inability to secure strategic partnerships or additional capital, leading to a severe cash crunch before 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.